Renaissance Technologies’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-88,229
| Closed | -$40K | – | 4094 |
|
|
2024
Q1 | $40K | Buy |
88,229
+31,262
| +55% | +$23.7K | ﹤0.01% | 3517 |
|
|
2023
Q4 | $42K | Buy |
+56,967
| New | +$41.6K | ﹤0.01% | 3484 |
|
|
2023
Q3 | – | Sell |
-12,601
| Closed | -$24K | – | 4232 |
|
|
2023
Q2 | $24K | Buy |
12,601
+3,970
| +46% | +$13.1K | ﹤0.01% | 3744 |
|
|
2023
Q1 | $32K | Sell |
8,631
-5,630
| -39% | -$26K | ﹤0.01% | 3751 |
|
|
2022
Q4 | $54K | Sell |
14,261
-108
| -0.8% | -$554 | ﹤0.01% | 3783 |
|
|
2022
Q3 | $114K | Buy |
14,369
+2,412
| +20% | +$39.9K | ﹤0.01% | 3550 |
|
|
2022
Q2 | $251K | Buy |
11,957
+1,215
| +11% | +$28.5K | ﹤0.01% | 3546 |
|
|
2022
Q1 | $404K | Buy |
10,742
+4,623
| +76% | +$160K | ﹤0.01% | 3319 |
|
|
2021
Q4 | $344K | Sell |
6,119
-13,441
| -69% | -$902K | ﹤0.01% | 3274 |
|
|
2021
Q3 | $1.41M | Sell |
19,560
-1,683
| -8% | -$129K | ﹤0.01% | 2355 |
|
|
2021
Q2 | $2.04M | Buy |
21,243
+11,449
| +117% | +$1.26M | ﹤0.01% | 2253 |
|
|
2021
Q1 | $1.45M | Sell |
9,794
-11,325
| -54% | -$2.05M | ﹤0.01% | 2418 |
|
|
2020
Q4 | $2.95M | Sell |
21,119
-6,718
| -24% | -$1.09M | ﹤0.01% | 1905 |
|
|
2020
Q3 | $4.23M | Sell |
27,837
-16,967
| -38% | -$2.77M | ﹤0.01% | 1669 |
|
|
2020
Q2 | $7.87M | Buy |
44,804
+25,730
| +135% | +$4.31M | 0.01% | 1372 |
|
|
2020
Q1 | $2.72M | Buy |
19,074
+1,414
| +8% | +$187K | ﹤0.01% | 1895 |
|
|
2019
Q4 | $2.54M | Buy |
17,660
+4,784
| +37% | +$561K | ﹤0.01% | 2200 |
|
|
2019
Q3 | $1.28M | Buy |
12,876
+2,185
| +20% | +$216K | ﹤0.01% | 2492 |
|
|
2019
Q2 | $729K | Buy |
10,691
+2,271
| +27% | +$129K | ﹤0.01% | 2842 |
|
|
2019
Q1 | $379K | Buy |
8,420
+3,461
| +70% | +$166K | ﹤0.01% | 3031 |
|
|
2018
Q4 | $171K | Buy |
4,959
+1,105
| +29% | +$80K | ﹤0.01% | 3162 |
|
|
2018
Q3 | $285K | Buy |
3,854
+578
| +18% | +$43.6K | ﹤0.01% | 3033 |
|
|
2018
Q2 | $257K | Buy |
3,276
+420
| +15% | +$36.6K | ﹤0.01% | 3014 |
|
|
2018
Q1 | $251K | Buy |
2,856
+231
| +9% | +$34.4K | ﹤0.01% | 3129 |
|
|
2017
Q4 | $1.95M | Buy |
2,625
+654
| +33% | +$253K | ﹤0.01% | 2360 |
|
|
2017
Q3 | $568K | Buy |
1,971
+513
| +35% | +$140K | ﹤0.01% | 2759 |
|
|
2017
Q2 | $373K | Buy |
1,458
+884
| +154% | +$237K | ﹤0.01% | 2836 |
|
|
2017
Q1 | $191K | Buy |
574
+406
| +242% | +$188K | ﹤0.01% | 3007 |
|
|
2016
Q4 | $101K | Buy |
168
+41
| +32% | +$43.3K | ﹤0.01% | 3101 |
|
|
2016
Q3 | $143K | Buy |
127
+72
| +131% | +$77.7K | ﹤0.01% | 3130 |
|
|
2016
Q2 | $60K | Buy |
+55
| New | +$69.1K | ﹤0.01% | 3222 |
|
Other funds holding NBSE
Renaissance Technologies's NBSE Position: Q2 2024 in Review
Renaissance Technologies sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2024, closing a stake of 88,229 shares — an estimated $40K sold.
Renaissance Technologies first reported a position in NBSE in Q2 2016 and held it in 31 quarters. The position peaked at $7.87M in Q2 2020. 3 funds tracked by Wall St. Rank hold NBSE as of Q2 2024.
- Renaissance Technologies reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Renaissance Technologies sold 88,229 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $40K.
- Renaissance Technologies first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2016 and held it in 31 quarters.
- Renaissance Technologies's NeuBase Therapeutics, Inc. Common Stock position peaked at $7.87M in Q2 2020.
- 3 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2024.
Based on Renaissance Technologies's 13F filing for Q2 2024, filed 9 Aug 2024.